AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
Part of paid clinical trials in Duarte, California.
- Sponsor
- Arsenal Biosciences, Inc.
- Study ID
- NCT07285694
- Phase
- PHASE1/PHASE2
- Status
- Recruiting
Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- AB-3028 — BIOLOGICALautologous T cell therapy
Study Details
This is a multi-center, open-label Phase 1/2 trial evaluating the safety and efficacy of AB-3028 in subjects with metastatic castration resistant prostate cancer (mCRPC).
Key Dates
- Start date
- Jan 9, 2026
- Status verified
- Jun 2026
- Primary completion
- May 31, 2029
- Completion
- May 31, 2031
Study Design
- Enrollment
- 190 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: AB-3028Patients receive a single dose of AB-3028 intravenously on day 0.
Primary Outcome Measure
Safety and tolerability of AB-3028 [ Time Frame: From AB-3028 infusion up to 24 months post-infusion ]
Central Contacts
- Arsenal Biosciences, Inc.650-446-4874
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope | Duarte | California | 91010 | Clinical Trials Line 626-218-1133 |
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | |
| University of California, San Francisco | San Francisco | California | 94143 | |
| University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) | Aurora | Colorado | 80045 | - |
| University of Iowa and Holden Comprehensive Cancer Center | Iowa City | Iowa | 52242 | Clinical trial intake (Genitourinary Cancer) |
| The University of Kansas Cancer Center | Fairway | Kansas | 66205 | - |
| University of Minnesota | Minneapolis | Minnesota | 55455 | - |
| Perlmutter Cancer Center - NYU Langone Health | New York | New York | 10016 | - |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 |
Find similar trials in Duarte, CA
By research site
City of Hope· Duarte, CAUSC Norris Comprehensive Cancer Center· Los Angeles, CAUniversity of California, San Francisco· San Francisco, CAUniversity of Colorado Hospital - Anschutz Inpatient Pavilion (AIP)· Aurora, COUniversity of Iowa and Holden Comprehensive Cancer Center· Iowa City, IAThe University of Kansas Cancer Center· Fairway, KS
Related Studies
- A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaPHASE1 · Recruiting · Pfizer · Tucson, Arizona